Robeco Institutional Asset Management B.V. Trims Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Robeco Institutional Asset Management B.V. trimmed its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 2.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 174,484 shares of the biotechnology company’s stock after selling 4,600 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.07% of ADMA Biologics worth $2,992,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ADMA. USA Financial Formulas increased its position in shares of ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 539 shares during the last quarter. Vontobel Holding Ltd. boosted its stake in ADMA Biologics by 7.0% during the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after buying an additional 888 shares during the period. GAMMA Investing LLC increased its position in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 967 shares during the last quarter. Hollencrest Capital Management purchased a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $30,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of ADMA Biologics by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 1,509 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $16.15 on Monday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52-week low of $5.02 and a 52-week high of $23.64. The firm has a market cap of $3.82 billion, a PE ratio of 57.68 and a beta of 0.76. The company’s 50 day moving average is $18.10 and its two-hundred day moving average is $17.61.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the business posted $0.01 earnings per share. On average, research analysts expect that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ADMA. Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright lifted their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.